Skip to main content
Erschienen in: Cancer Immunology, Immunotherapy 1/2021

17.07.2020 | Original Article

Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels tumour heterogeneity plus M2-like tumour-associated macrophage infiltration and aggressiveness in TNBC

verfasst von: Xuanwen Bao, Run Shi, Tianyu Zhao, Yanfang Wang, Natasa Anastasov, Michael Rosemann, Weijia Fang

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Triple-negative breast cancer (TNBC) is characterized by a more aggressive clinical course with extensive inter- and intra-tumour heterogeneity. Combination of single-cell and bulk tissue transcriptome profiling allows the characterization of tumour heterogeneity and identifies the association of the immune landscape with clinical outcomes. We identified inter- and intra-tumour heterogeneity at a single-cell resolution. Tumour cells shared a high correlation amongst stemness, angiogenesis, and EMT in TNBC. A subset of cells with concurrent high EMT, stemness and angiogenesis was identified at the single-cell level. Amongst tumour-infiltrating immune cells, M2-like tumour-associated macrophages (TAMs) made up the majority of macrophages and displayed immunosuppressive characteristics. CIBERSORT was applied to estimate the abundance of M2-like TAM in bulk tissue transcriptome file from The Cancer Genome Atlas (TCGA). M2-like TAMs were associated with unfavourable prognosis in TNBC patients. A TAM-related gene signature serves as a promising marker for predicting prognosis and response to immunotherapy. Two commonly used machine learning methods, random forest and SVM, were applied to find the genes that were mostly associated with M2-like TAM densities in the gene signature. A neural network-based deep learning framework based on the TAM-related gene signature exhibits high accuracy in predicting the immunotherapy response.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. N Engl J Med 363(20):1938–1948CrossRef Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. N Engl J Med 363(20):1938–1948CrossRef
2.
Zurück zum Zitat Chung W, Eum HH, Lee H-O, Lee K-M, Lee H-B, Kim K-T et al (2017) Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer. Nat Commun 8(1):1–12CrossRef Chung W, Eum HH, Lee H-O, Lee K-M, Lee H-B, Kim K-T et al (2017) Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer. Nat Commun 8(1):1–12CrossRef
3.
Zurück zum Zitat Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y et al (2012) The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486(7403):395–399CrossRef Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y et al (2012) The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486(7403):395–399CrossRef
4.
Zurück zum Zitat Karaayvaz M, Cristea S, Gillespie SM, Patel AP, Mylvaganam R, Luo CC et al (2018) Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq. Nat Commun 9(1):1–10CrossRef Karaayvaz M, Cristea S, Gillespie SM, Patel AP, Mylvaganam R, Luo CC et al (2018) Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq. Nat Commun 9(1):1–10CrossRef
5.
Zurück zum Zitat Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA et al (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26(8):1275–1281CrossRef Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA et al (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26(8):1275–1281CrossRef
6.
Zurück zum Zitat Hoadley KA, Siegel MB, Kanchi KL, Miller CA, Ding L, Zhao W et al (2016) Tumor evolution in two patients with basal-like breast cancer: a retrospective genomics study of multiple metastases. PLoS Med 13(12):e1002174CrossRef Hoadley KA, Siegel MB, Kanchi KL, Miller CA, Ding L, Zhao W et al (2016) Tumor evolution in two patients with basal-like breast cancer: a retrospective genomics study of multiple metastases. PLoS Med 13(12):e1002174CrossRef
7.
Zurück zum Zitat Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F et al (2013) Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 31(7):860–867CrossRef Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F et al (2013) Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 31(7):860–867CrossRef
8.
Zurück zum Zitat Keren L, Bosse M, Marquez D, Angoshtari R, Jain S, Varma S et al (2018) A structured tumor-immune microenvironment in triple negative breast cancer revealed by multiplexed ion beam imaging. Cell. 174(6):1373–87.e19CrossRef Keren L, Bosse M, Marquez D, Angoshtari R, Jain S, Varma S et al (2018) A structured tumor-immune microenvironment in triple negative breast cancer revealed by multiplexed ion beam imaging. Cell. 174(6):1373–87.e19CrossRef
9.
Zurück zum Zitat Brown SD, Warren RL, Gibb EA, Martin SD, Spinelli JJ, Nelson BH et al (2014) Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res 24(5):743–750CrossRef Brown SD, Warren RL, Gibb EA, Martin SD, Spinelli JJ, Nelson BH et al (2014) Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res 24(5):743–750CrossRef
10.
Zurück zum Zitat Bao X, Shi R, Zhang K, Xin S, Li X, Zhao Y et al (2019) Immune landscape of invasive ductal carcinoma tumor microenvironment identifies a prognostic and immunotherapeutically relevant gene signature. Front Oncol 9:903CrossRef Bao X, Shi R, Zhang K, Xin S, Li X, Zhao Y et al (2019) Immune landscape of invasive ductal carcinoma tumor microenvironment identifies a prognostic and immunotherapeutically relevant gene signature. Front Oncol 9:903CrossRef
11.
Zurück zum Zitat Bao X, Anastasov N, Wang Y, Rosemann M (2019) A novel epigenetic signature for overall survival prediction in patients with breast cancer. J Transl Med 17(1):380CrossRef Bao X, Anastasov N, Wang Y, Rosemann M (2019) A novel epigenetic signature for overall survival prediction in patients with breast cancer. J Transl Med 17(1):380CrossRef
12.
Zurück zum Zitat Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD (2012) The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics 28(6):882–883CrossRef Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD (2012) The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics 28(6):882–883CrossRef
13.
Zurück zum Zitat Butler A, Hoffman P, Smibert P, Papalexi E, Satija R (2018) Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat Biotechnol 36(5):411–420CrossRef Butler A, Hoffman P, Smibert P, Papalexi E, Satija R (2018) Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat Biotechnol 36(5):411–420CrossRef
14.
Zurück zum Zitat Hänzelmann S, Castelo R, Guinney J (2013) GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform 14(1):7CrossRef Hänzelmann S, Castelo R, Guinney J (2013) GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform 14(1):7CrossRef
15.
Zurück zum Zitat Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA (2018) Profiling tumor infiltrating immune cells with CIBERSORT. Springer, Cancer Syst Biol, pp 243–259 Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA (2018) Profiling tumor infiltrating immune cells with CIBERSORT. Springer, Cancer Syst Biol, pp 243–259
16.
Zurück zum Zitat Langfelder P, Horvath S (2008) WGCNA: an R package for weighted correlation network analysis. BMC Bioinform 9(1):559CrossRef Langfelder P, Horvath S (2008) WGCNA: an R package for weighted correlation network analysis. BMC Bioinform 9(1):559CrossRef
17.
Zurück zum Zitat Therneau TM, Grambsch PM (2000) The Cox model. In: Modeling survival data: extending the Cox model. Statistics for Biology and Health. Springer, New York, NY, pp 39–77CrossRef Therneau TM, Grambsch PM (2000) The Cox model. In: Modeling survival data: extending the Cox model. Statistics for Biology and Health. Springer, New York, NY, pp 39–77CrossRef
18.
Zurück zum Zitat Wilkerson MD, Hayes DN (2010) ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics 26(12):1572–1573CrossRef Wilkerson MD, Hayes DN (2010) ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics 26(12):1572–1573CrossRef
19.
Zurück zum Zitat Ritchie ME, Phipson B, Wu DI, Hu Y, Law CW, Shi W, Smyth GK (2015) limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 43(7):e47–e47CrossRef Ritchie ME, Phipson B, Wu DI, Hu Y, Law CW, Shi W, Smyth GK (2015) limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 43(7):e47–e47CrossRef
20.
Zurück zum Zitat Wright MN, Ziegler A (2015) Ranger: a fast implementation of random forests for high dimensional data in C ++ and R. arXiv preprint arXiv:150804409 Wright MN, Ziegler A (2015) Ranger: a fast implementation of random forests for high dimensional data in C ++ and R. arXiv preprint arXiv:​150804409
21.
Zurück zum Zitat Liaw A, Wiener M (2002) Classification and regression by randomForest. R News. 2(3):18–22 Liaw A, Wiener M (2002) Classification and regression by randomForest. R News. 2(3):18–22
23.
Zurück zum Zitat Paszke A, Gross S, Chintala S, Chanan G, Yang E, DeVito Z, et al (2017) Automatic differentiation in pytorch Paszke A, Gross S, Chintala S, Chanan G, Yang E, DeVito Z, et al (2017) Automatic differentiation in pytorch
24.
Zurück zum Zitat Tsai CH, Chiu JH, Yang CW, Wang JY, Tsai YF, Tseng LM et al (2015) Molecular characteristics of recurrent triple-negative breast cancer. Mol Med Rep 12(5):7326–7334CrossRef Tsai CH, Chiu JH, Yang CW, Wang JY, Tsai YF, Tseng LM et al (2015) Molecular characteristics of recurrent triple-negative breast cancer. Mol Med Rep 12(5):7326–7334CrossRef
25.
Zurück zum Zitat Linderholm B, Hellborg H, Johansson U, Elmberger G, Skoog L, Lehtiö J et al (2009) Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann Oncol 20(10):1639–1646CrossRef Linderholm B, Hellborg H, Johansson U, Elmberger G, Skoog L, Lehtiö J et al (2009) Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann Oncol 20(10):1639–1646CrossRef
26.
Zurück zum Zitat Bulfoni M, Gerratana L, Del Ben F, Marzinotto S, Sorrentino M, Turetta M et al (2016) In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis. Breast Cancer Res 18(1):30CrossRef Bulfoni M, Gerratana L, Del Ben F, Marzinotto S, Sorrentino M, Turetta M et al (2016) In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis. Breast Cancer Res 18(1):30CrossRef
27.
Zurück zum Zitat Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell. 144(5):646–674CrossRef Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell. 144(5):646–674CrossRef
28.
Zurück zum Zitat Teng MW, Ngiow SF, Ribas A, Smyth MJ (2015) Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res 75(11):2139–2145CrossRef Teng MW, Ngiow SF, Ribas A, Smyth MJ (2015) Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res 75(11):2139–2145CrossRef
29.
Zurück zum Zitat Su S, Liu Q, Chen J, Chen J, Chen F, He C et al (2014) A positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis. Cancer Cell 25(5):605–620CrossRef Su S, Liu Q, Chen J, Chen J, Chen F, He C et al (2014) A positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis. Cancer Cell 25(5):605–620CrossRef
30.
Zurück zum Zitat Gwak JM, Jang MH, Kim DI, Seo AN, Park SY (2015) Prognostic value of tumor-associated macrophages according to histologic locations and hormone receptor status in breast cancer. PloS One 10(4):e0125728CrossRef Gwak JM, Jang MH, Kim DI, Seo AN, Park SY (2015) Prognostic value of tumor-associated macrophages according to histologic locations and hormone receptor status in breast cancer. PloS One 10(4):e0125728CrossRef
31.
Zurück zum Zitat Shirabe K, Mano Y, Muto J, Matono R, Motomura T, Toshima T et al (2012) Role of tumor-associated macrophages in the progression of hepatocellular carcinoma. Surg Today 42(1):1–7CrossRef Shirabe K, Mano Y, Muto J, Matono R, Motomura T, Toshima T et al (2012) Role of tumor-associated macrophages in the progression of hepatocellular carcinoma. Surg Today 42(1):1–7CrossRef
32.
Zurück zum Zitat Yang Z, Xie H, He D, Li L (2016) Infiltrating macrophages increase RCC epithelial mesenchymal transition (EMT) and stem cell-like populations via AKT and mTOR signaling. Oncotarget. 7(28):44478CrossRef Yang Z, Xie H, He D, Li L (2016) Infiltrating macrophages increase RCC epithelial mesenchymal transition (EMT) and stem cell-like populations via AKT and mTOR signaling. Oncotarget. 7(28):44478CrossRef
33.
Zurück zum Zitat Ruchat S-M, Houde A-A, Voisin G, St-Pierre J, Perron P, Baillargeon J-P et al (2013) Gestational diabetes mellitus epigenetically affects genes predominantly involved in metabolic diseases. Epigenetics. 8(9):935–943CrossRef Ruchat S-M, Houde A-A, Voisin G, St-Pierre J, Perron P, Baillargeon J-P et al (2013) Gestational diabetes mellitus epigenetically affects genes predominantly involved in metabolic diseases. Epigenetics. 8(9):935–943CrossRef
34.
Zurück zum Zitat Coelho D, Kim JC, Miousse IR, Fung S, du Moulin M, Buers I et al (2012) Mutations in ABCD4 cause a new inborn error of vitamin B 12 metabolism. Nat Genet 44(10):1152–1155CrossRef Coelho D, Kim JC, Miousse IR, Fung S, du Moulin M, Buers I et al (2012) Mutations in ABCD4 cause a new inborn error of vitamin B 12 metabolism. Nat Genet 44(10):1152–1155CrossRef
35.
Zurück zum Zitat Donovan A, Lima CA, Pinkus JL, Pinkus GS, Zon LI, Robine S et al (2005) The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. Cell Metab 1(3):191–200CrossRef Donovan A, Lima CA, Pinkus JL, Pinkus GS, Zon LI, Robine S et al (2005) The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. Cell Metab 1(3):191–200CrossRef
36.
Zurück zum Zitat Goulart AC, Rexrode KM, Cheng S, Rose L, Buring JE, Ridker PM et al (2009) Association of genetic variants with the metabolic syndrome in 20,806 white women: the women’s health genome study. Am Heart J. 158(2):257–62.e1CrossRef Goulart AC, Rexrode KM, Cheng S, Rose L, Buring JE, Ridker PM et al (2009) Association of genetic variants with the metabolic syndrome in 20,806 white women: the women’s health genome study. Am Heart J. 158(2):257–62.e1CrossRef
37.
Zurück zum Zitat Noy R, Pollard JW (2014) Tumor-associated macrophages: from mechanisms to therapy. Immunity 41(1):49–61CrossRef Noy R, Pollard JW (2014) Tumor-associated macrophages: from mechanisms to therapy. Immunity 41(1):49–61CrossRef
38.
Zurück zum Zitat Tariq M, Zhang J, Liang G, Ding L, He Q, Yang B (2017) Macrophage polarization: anti-cancer strategies to target tumor-associated macrophage in breast cancer. J Cell Biochem 118(9):2484–2501CrossRef Tariq M, Zhang J, Liang G, Ding L, He Q, Yang B (2017) Macrophage polarization: anti-cancer strategies to target tumor-associated macrophage in breast cancer. J Cell Biochem 118(9):2484–2501CrossRef
39.
Zurück zum Zitat Strachan DC, Ruffell B, Oei Y, Bissell MJ, Coussens LM, Pryer N et al (2013) CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8 + T cells. Oncoimmunology. 2(12):e26968CrossRef Strachan DC, Ruffell B, Oei Y, Bissell MJ, Coussens LM, Pryer N et al (2013) CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8 + T cells. Oncoimmunology. 2(12):e26968CrossRef
40.
Zurück zum Zitat Zhu Y, Knolhoff BL, Meyer MA, Nywening TM, West BL, Luo J et al (2014) CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res 74(18):5057–5069CrossRef Zhu Y, Knolhoff BL, Meyer MA, Nywening TM, West BL, Luo J et al (2014) CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res 74(18):5057–5069CrossRef
41.
Zurück zum Zitat Seidel JA, Otsuka A, Kabashima K (2018) Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. Front Oncol 8:86CrossRef Seidel JA, Otsuka A, Kabashima K (2018) Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. Front Oncol 8:86CrossRef
Metadaten
Titel
Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels tumour heterogeneity plus M2-like tumour-associated macrophage infiltration and aggressiveness in TNBC
verfasst von
Xuanwen Bao
Run Shi
Tianyu Zhao
Yanfang Wang
Natasa Anastasov
Michael Rosemann
Weijia Fang
Publikationsdatum
17.07.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
Cancer Immunology, Immunotherapy / Ausgabe 1/2021
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-020-02669-7

Weitere Artikel der Ausgabe 1/2021

Cancer Immunology, Immunotherapy 1/2021 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.